Tadashi Toki - Concepedia

Author

Tadashi Toki

Daiichi-Sankyo (Japan)ORCID

Also Known As

Tadashi Toki

Publications

352

Citations

H-Index

Concepts

All Affiliations

Daiichi-Sankyo (Japan)Daiichi Sankyo (Germany)The University of Tokyo

About

Tadashi Toki is an author at Daiichi-Sankyo (Japan) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	141
2	Biochemistry	4	4	105
3	Natural Sciences	2	2	35
4	Immunology	2	2	36
5	Cell Biology	1	1	16

Tadashi Toki

Publications

339

Citations

H-Index

Page 1

	Year	Citations
Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity Junya Kawai, Tadashi Toki, Masahiro Ota, Journal of Medicinal Chemistry	2019	80
Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database Tadashi Toki, Shunsuke Ono Drugs - Real World Outcomes	2018	74
Structure-Based Design and Synthesis of an Isozyme-Selective MTHFD2 Inhibitor with a Tricyclic Coumarin Scaffold Junya Kawai, Masahiro Ota, Hitoshi Ohki, ACS Medicinal Chemistry Letters Combinatorial ChemistryAldehyde DehydrogenaseBiochemistryMedicineRational Drug Design	2019	46
Lipopolysaccharide accelerates collagen‐induced arthritis in association with rapid and continuous production of inflammatory mediators and anti‐type <scp>II</scp> collagen antibody Shinji Tanaka, Tadashi Toki, Toshihiko Akimoto, Microbiology and Immunology	2013	26
Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models H. Shimizu, Tomonori Yamasaki, Yoshiyuki Yoneda, Bioorganic & Medicinal Chemistry Letters RheumatologyAnti-inflammatoryBiochemistryMedicineRational Drug Design	2011	24
Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC). Aaron Lisberg, Jacob Sands, Toshio Shimizu, Journal of Clinical Oncology Tumor BiologyDose EscalationMedicineImmunologyPharmacology	2020	20
Discovery of imidazo[1,2-b]pyridazine derivatives as IKKβ inhibitors. Part 1: Hit-to-lead study and structure–activity relationship H. Shimizu, Shinji Tanaka, Tadashi Toki, Bioorganic & Medicinal Chemistry Letters Structure–activity RelationshipMedicinal ChemistryBiochemistryMedicineNatural Sciences	2010	18
Assessment of factors associated with completeness of spontaneous adverse event reporting in the United States: A comparison between consumer reports and healthcare professional reports Tadashi Toki, Shunsuke Ono Journal of Clinical Pharmacy and Therapeutics	2019	18
Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: Improvement of potency in vitro and in vivo H. Shimizu, Isao Yasumatsu, Tomoaki Hamada, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNatural SciencesMechanism Of Action	2010	17
Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd. Daisuke Okajima, Satoru Yasuda, Yusuke Yokouchi, Journal of Clinical Oncology Novel Dna TopoisomeraseImmunologyImmunotherapyCancer BiologyTumor Biology	2018	16

Page 1